FindTrial
Sign In

A follow-up study to explore the effects of Escitalopram treatment on the process of ageing and related disorders in individuals with Major Depressive Disorder (MDD)

Study on the Role of Senescence and Neurodegenerative Biomarkers in Major Depressive Disorder subject during Escitalopram treatment - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097524
Enrollment
65
Registered
2025-11-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F339- Major depressive disorder, recurrent, unspecified Health Condition 2: F329- Major depressive disorder, singleepisode, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Escitalopram: 10 mg OD, Oral for 6 months Control Intervention1: Not Applicable: Not Applicable

Sponsors

Dr. Neelam Yeram
Lead Sponsor
Dr Mansee Thakur
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals diagnosed with Major Depressive Disorder based on structured clinical questionnaire as per DSM 5 criteria (American Psychiatric Association, 2013) and prescribed for Escitalopram treatment by Psychiatrists will be included in the study. 2. Individuals of both sexes in the age group of 18 to 35 years will be included. 3. Individuals willing to participate in the study will be included.

Exclusion criteria

Exclusion criteria: 1. Individuals suffering from Head injury, cerebral stroke, dementia, chronic diabetes, poisoning, schizophrenia, chronic alcoholism or any other severe mental illness and disease affecting brain except Depression will be excluded from the study. 2. The individuals not willing to participate in the study were excluded from the study. 3. Individuals having the last 2 months history of drug treatment with significant central serotonergic effects or any investigational treatment for MDD will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Variations in the Neurodegenerative and Senescence Blood Biomarkers in MDD Subjects undergoing Escitalopram treatmentTimepoint: At 0, 3 and 6 months interval—

Secondary

MeasureTime frame
Expressions of Ras p21, p16 and p53 genes in bloodTimepoint: At 0, 3 and 6 months interval;Senescence associated beta galactosidase activity in bloodTimepoint: At 0, 3 and 6 months interval;Serum levels of beta amyloid peptide, Tau protein, neurofilament light and Glial fibrillary acidic proteinTimepoint: At 0, 3 and 6 months interval;Gene expression of serotonin receptor 2A, apolipoprotein E and amyloid precursor protein in bloodTimepoint: At 0, 3 and 6 months interval;Blood levels of Cortisol, Serotonin and HomocysteineTimepoint: At 0, 3 and 6 months interval—

Countries

India

Contacts

Public ContactDr Neelam Yeram

MGM School of Biomedical Sciences, Navi Mumbai

neelamyeram21@gmail.com08454016003

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026